Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Published

Journal Article (Review)

INTRODUCTION: Ramucirumab (IMC-1121B) is a fully humanized IgG1 monoclonal antibody, targeting the extracellular domain of VEGF receptor 2 (VEGFR2). Numerous Phase I - II trials in various malignancies have shown promising clinical antitumor efficacy and tolerability. Most recently, the large Phase III REGARD trial evaluated ramucirumab in patients with refractory metastatic gastric cancer. Patients receiving ramucirumab experienced a median overall survival of 5.2 months compared to 3.8 months on placebo. AREAS COVERED: The purpose of this article is to review the preclinical motivation for VEGFR2-targeted therapies and survey recent data from clinical trials involving ramucirumab, as well as highlight ongoing studies. EXPERT OPINION: Rational multi-target approaches to angiogenesis are needed to overcome resistance mechanisms. Predictive angiogenic biomarkers are also needed to optimize patient selection for novel anti-angiogenic agents.

Full Text

Duke Authors

Cited Authors

  • Clarke, JM; Hurwitz, HI

Published Date

  • August 2013

Published In

Volume / Issue

  • 13 / 8

Start / End Page

  • 1187 - 1196

PubMed ID

  • 23803182

Pubmed Central ID

  • 23803182

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

Digital Object Identifier (DOI)

  • 10.1517/14712598.2013.810717

Language

  • eng

Conference Location

  • England